Logo image of NBY

NOVABAY PHARMACEUTICALS INC (NBY) Stock Fundamental Analysis

NYSEARCA:NBY - NYSE Arca - US66987P4090 - Common Stock - Currency: USD

0.63  -0.01 (-2.1%)

After market: 0.65 +0.02 (+3.17%)

Fundamental Rating

2

Overall NBY gets a fundamental rating of 2 out of 10. We evaluated NBY against 194 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of NBY have multiple concerns. NBY does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

NBY had negative earnings in the past year.
NBY had a negative operating cash flow in the past year.
In the past 5 years NBY always reported negative net income.
In the past 5 years NBY always reported negative operating cash flow.
NBY Yearly Net Income VS EBIT VS OCF VS FCFNBY Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -5M -10M -15M -20M

1.2 Ratios

The Return On Assets of NBY (-427.26%) is worse than 95.14% of its industry peers.
NBY has a Return On Equity of -1545.24%. This is amonst the worse of the industry: NBY underperforms 86.49% of its industry peers.
Industry RankSector Rank
ROA -427.26%
ROE -1545.24%
ROIC N/A
ROA(3y)-103.8%
ROA(5y)-95.46%
ROE(3y)-240.85%
ROE(5y)-378.72%
ROIC(3y)N/A
ROIC(5y)N/A
NBY Yearly ROA, ROE, ROICNBY Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -1K -2K -3K

1.3 Margins

NBY's Gross Margin of 60.67% is fine compared to the rest of the industry. NBY outperforms 67.03% of its industry peers.
In the last couple of years the Gross Margin of NBY has declined.
The Profit Margin and Operating Margin are not available for NBY so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 60.67%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.69%
GM growth 5Y-9.44%
NBY Yearly Profit, Operating, Gross MarginsNBY Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -100 -200 -300 -400

More info and screens

2

2. Health

2.1 Basic Checks

NBY does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for NBY has been reduced compared to 1 year ago.
The number of shares outstanding for NBY has been reduced compared to 5 years ago.
NBY has a worse debt/assets ratio than last year.
NBY Yearly Shares OutstandingNBY Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 500K 1M 1.5M 2M
NBY Yearly Total Debt VS Total AssetsNBY Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M 20M

2.2 Solvency

Based on the Altman-Z score of -65.97, we must say that NBY is in the distress zone and has some risk of bankruptcy.
NBY has a Altman-Z score of -65.97. This is amonst the worse of the industry: NBY underperforms 93.51% of its industry peers.
A Debt/Equity ratio of 0.05 indicates that NBY is not too dependend on debt financing.
With a Debt to Equity ratio value of 0.05, NBY perfoms like the industry average, outperforming 50.81% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.05
Debt/FCF N/A
Altman-Z -65.97
ROIC/WACCN/A
WACC15.96%
NBY Yearly LT Debt VS Equity VS FCFNBY Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 10M -10M

2.3 Liquidity

A Current Ratio of 1.15 indicates that NBY should not have too much problems paying its short term obligations.
With a Current ratio value of 1.15, NBY is not doing good in the industry: 83.24% of the companies in the same industry are doing better.
A Quick Ratio of 0.91 indicates that NBY may have some problems paying its short term obligations.
NBY has a Quick ratio of 0.91. This is amonst the worse of the industry: NBY underperforms 83.78% of its industry peers.
Industry RankSector Rank
Current Ratio 1.15
Quick Ratio 0.91
NBY Yearly Current Assets VS Current LiabilitesNBY Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M

More info and screens

3

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 42.10% over the past year.
Looking at the last year, NBY shows a very negative growth in Revenue. The Revenue has decreased by -23.50% in the last year.
NBY shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 3.32% yearly.
EPS 1Y (TTM)42.1%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%97.45%
Revenue 1Y (TTM)-23.5%
Revenue growth 3Y14.04%
Revenue growth 5Y3.32%
Sales Q2Q%-25.24%

3.2 Future

The Earnings Per Share is expected to grow by 25.92% on average over the next years. This is a very strong growth
NBY is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 3.24% yearly.
EPS Next Y98.72%
EPS Next 2Y41.15%
EPS Next 3Y25.92%
EPS Next 5YN/A
Revenue Next Year-25.41%
Revenue Next 2Y-6.46%
Revenue Next 3Y3.24%
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
NBY Yearly Revenue VS EstimatesNBY Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 5M 10M 15M
NBY Yearly EPS VS EstimatesNBY Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 -2K -4K -6K -8K

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

NBY reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year NBY is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NBY Price Earnings VS Forward Price EarningsNBY Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NBY Per share dataNBY EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -10 -20 -30 -40 -50

4.3 Compensation for Growth

NBY's earnings are expected to grow with 25.92% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y41.15%
EPS Next 3Y25.92%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for NBY!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NOVABAY PHARMACEUTICALS INC

NYSEARCA:NBY (2/21/2025, 8:04:00 PM)

After market: 0.65 +0.02 (+3.17%)

0.63

-0.01 (-2.1%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-07 2024-11-07/amc
Earnings (Next)03-24 2025-03-24/amc
Inst Owners16.13%
Inst Owner Change32.59%
Ins Owners0.02%
Ins Owner Change0%
Market Cap3.08M
Analysts80
Price Target0.87 (38.1%)
Short Float %1.67%
Short Ratio0.29
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-8.93%
Min EPS beat(2)-10.73%
Max EPS beat(2)-7.13%
EPS beat(4)1
Avg EPS beat(4)-88.95%
Min EPS beat(4)-338.94%
Max EPS beat(4)0.99%
EPS beat(8)3
Avg EPS beat(8)-88.44%
EPS beat(12)4
Avg EPS beat(12)-75.68%
EPS beat(16)7
Avg EPS beat(16)-57.37%
Revenue beat(2)0
Avg Revenue beat(2)-16.26%
Min Revenue beat(2)-24.67%
Max Revenue beat(2)-7.85%
Revenue beat(4)1
Avg Revenue beat(4)-11.15%
Min Revenue beat(4)-24.67%
Max Revenue beat(4)8.53%
Revenue beat(8)2
Avg Revenue beat(8)-7.74%
Revenue beat(12)4
Avg Revenue beat(12)-6.68%
Revenue beat(16)5
Avg Revenue beat(16)-5.58%
PT rev (1m)-77.18%
PT rev (3m)-88.36%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-29.41%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-29.51%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.46%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.28
P/FCF N/A
P/OCF N/A
P/B 2.87
P/tB 2.87
EV/EBITDA N/A
EPS(TTM)-53.5
EYN/A
EPS(NY)-0.87
Fwd EYN/A
FCF(TTM)-0.93
FCFYN/A
OCF(TTM)-0.92
OCFYN/A
SpS2.29
BVpS0.22
TBVpS0.22
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -427.26%
ROE -1545.24%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 60.67%
FCFM N/A
ROA(3y)-103.8%
ROA(5y)-95.46%
ROE(3y)-240.85%
ROE(5y)-378.72%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.69%
GM growth 5Y-9.44%
F-Score4
Asset Turnover2.89
Health
Industry RankSector Rank
Debt/Equity 0.05
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 5.88%
Cap/Sales 0.04%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.15
Quick Ratio 0.91
Altman-Z -65.97
F-Score4
WACC15.96%
ROIC/WACCN/A
Cap/Depr(3y)24.65%
Cap/Depr(5y)32.5%
Cap/Sales(3y)0.5%
Cap/Sales(5y)0.42%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)42.1%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%97.45%
EPS Next Y98.72%
EPS Next 2Y41.15%
EPS Next 3Y25.92%
EPS Next 5YN/A
Revenue 1Y (TTM)-23.5%
Revenue growth 3Y14.04%
Revenue growth 5Y3.32%
Sales Q2Q%-25.24%
Revenue Next Year-25.41%
Revenue Next 2Y-6.46%
Revenue Next 3Y3.24%
Revenue Next 5YN/A
EBIT growth 1Y35.03%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year20.97%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y54.23%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y53.72%
OCF growth 3YN/A
OCF growth 5YN/A